LSU Receives Nearly $2 Million to Develop Bird Flu Vaccine That Could Protect Chickens Before They Hatch
Researchers at Louisiana State University have received nearly $2 million in federal funding to develop a bird flu vaccine that could protect chickens before they even hatch.
The project comes as highly pathogenic avian influenza, commonly known as H5N1 bird flu, continues to threaten poultry producers and the nation's food supply.
Since 2022, the virus has resulted in the loss of more than 168 million commercial and backyard poultry birds nationwide, according to LSU.
Those losses have disrupted poultry production, contributed to egg shortages and increased costs for consumers.
Now, Louisiana researchers are investigating whether a different approach to vaccination could help prevent future outbreaks.
A vaccine delivered before chickens hatch
The research team is led by Dr. Mariano Carossino, an associate professor of veterinary pathology at the LSU School of Veterinary Medicine.
The USDA awarded the project nearly $2 million through its Animal and Plant Health Inspection Service.
Researchers are developing a vaccine that could be administered in two ways.
The first involves vaccinating chickens while they are still developing inside their eggs, a technique known as in ovo vaccination.
The second involves delivering the vaccine through drinking water after the birds hatch.
Both approaches could allow poultry producers to protect large numbers of birds without individually injecting each animal.
That would be particularly valuable for commercial operations managing thousands or hundreds of thousands of chickens.
How the vaccine would work
The project uses specialized molecules called nanobodies to direct vaccine components toward immune cells in the intestinal tract.
Researchers hope to stimulate protective immunity at the body's mucosal surfaces, where many infections begin.
The team is also investigating self-amplifying RNA and modified viral-vector technologies to generate a stronger immune response.
The goal is not simply to produce another vaccine.
Researchers want protection that can be delivered efficiently across commercial poultry operations while allowing veterinarians to distinguish vaccinated birds from naturally infected animals.
That distinction is important for disease surveillance and controlling future outbreaks.
Why bird flu remains a national problem
Highly pathogenic avian influenza is particularly destructive because of how quickly it can spread through poultry populations.
When the virus is detected in commercial flocks, disease-control measures often require the entire affected flock to be destroyed to prevent additional transmission.
That means an outbreak involving a relatively small number of infected birds can result in the loss of thousands or millions of animals.
The consequences extend beyond farms.
Poultry losses can disrupt supply chains, reduce egg production and contribute to higher grocery prices.
Wild migratory birds also carry the virus across North America, creating continuing opportunities for infection.
The disease has spread beyond poultry, including detections in dairy cattle beginning in 2024.
Why the research matters for Louisiana
Louisiana's agricultural economy includes poultry production, commercial farming and rural communities that depend on livestock operations.
The state also sits along major migratory bird routes.
Earlier this month, LSU's Wildlife Hospital confirmed bird flu in a goose exhibiting neurological symptoms and weakness.
Veterinarians warned that migrating waterfowl can carry the virus into areas where domestic poultry and other animals may be exposed.
The LSU vaccine project addresses the same broader challenge: developing tools that could reduce the damage caused when the virus circulates.
Successful vaccine research could eventually help poultry producers protect their flocks while reducing the economic consequences of outbreaks.
The vaccine is not ready for commercial use
There is an important limitation.
The LSU project is still in the research stage.
No H5N1 vaccine is currently authorized for widespread use in commercial poultry production in the United States.
Over the next three years, the research team plans to develop vaccine candidates, evaluate immune responses and conduct controlled experiments to determine whether vaccinated chickens are protected from the disease.
Even successful laboratory results would not automatically authorize widespread commercial use.
Additional regulatory review and practical implementation would be required.
What happens next?
The research is scheduled to continue over the next three years.
If successful, the project could eventually provide poultry producers with a new way to protect large flocks before outbreaks spread.
For consumers, the potential long-term benefit is a more resilient poultry supply and fewer disruptions associated with mass flock losses.
For Louisiana, the project places LSU researchers among the scientists working to solve one of the most consequential animal-health problems facing American agriculture.
The outcome remains uncertain, but the nearly $2 million federal award gives the university an opportunity to test an approach that could change how poultry producers manage bird flu.
Sources
- LSU School of Veterinary Medicine: Nearly $2 million grant to develop bird flu vaccine, November 12, 2026
- LSU: Fighting Bird Flu, Research Aims to Protect U.S. Poultry, November 9, 2026
- LSU: Bird Flu Risk Increases During Fall and Winter, November 4, 2026
- WAFB: LSU Researchers Explain Three-Year Vaccine Project, November 12, 2026
- 337.NEWS Public Records Repository — general repository; this grant has not been independently verified as archived.
Member discussion
337.NEWS discussion
Join the conversation.
Sign up to comment on this story and follow the local reporting behind it.